News Hub | News Direct

All Industries


Article thumbnail News Release

BDA Announces 2025 Bermuda Risk Summit Dates

Bermuda Business Development Agency

Hamilton, Bermuda, July 19 th 2024: The Bermuda Risk Summit is set to take place from March 10-12, 2025, at the Hamilton Princess & Beach Club. This premier event promises to bring together industry leaders and experts for three days of insightful discussions and networking opportunities. Kendaree Burgess, COO of the Bermuda Business Development Agency, remarked, " The 2025 Bermuda Risk Summit is a must attend event for Bermuda’s Risk sector, bringing together industry thought leadership, innovation and interest from those seeking to make Bermuda their domicile of choice. This event highlights Bermuda's leadership in risk management and offers a unique platform for industry experts to network and collaborate.” The 2024 Bermuda Risk Summit saw over 450 attendees, with 40% traveling from 30 different countries. The summit featured 50 industry-leading speakers, addressing crucial topics that shape the risk management landscape. Sponsorship Opportunities Sponsorship opportunities for the Bermuda Risk Summit 2025 are now available! Sponsors will have the chance to gain significant visibility and connect with influential leaders in the risk management sector. If you are interested in sponsorship, click here or email bermudarisk@bda.bm. Early Bird Registration and Accommodation Members of the public are encouraged to register early. An early bird rate of $395 will be available until September 30. To avoid disappointment, click here to reserve your hotel room online or call 1-441-295-3000, or the Global Reservations Centre at 1-800-441-1414, using the booking code: ‘Bermuda Risk Summit’ to take advantage of our preferred rate. For more information, please visit our website or contact us at bermudarisk@bda.bm. BERMUDA BUSINESS DEVELOPMENT AGENCY BDA.BM +1 441 292 0632 CONNECTING BUSINESS The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. The Bermuda Business Development Agency (BDA) encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Contact Details Bermuda’s Business Development Agency (BDA) Melvin Dickinson +1 441-707-0038 info@bda.bm Company Website https://bda.bm

July 19, 2024 01:56 PM Eastern Daylight Time

Article thumbnail News Release

Tonix Pharmaceuticals Awarded potential 34 million dollar Contract with U.S. Department of Defence

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to share exciting news about a significant achievement for the company. Tonix Pharmaceuticals has been awarded a potential contract worth up to $34 million over five years by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. This contract aims to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections, thereby enhancing the medical readiness of military personnel in biological threat environments. Dr. Lederman explained that Tonix’s program will concentrate on the optimization and development of its TNX-4200 program. The goal is to develop an orally available CD45 antagonist with broad-spectrum efficacy against various viral families through extensive preclinical evaluation. The program is expected to establish essential physicochemical properties, pharmacokinetics, and safety attributes to support an Investigational New Drug (IND) submission, ultimately funding a first-in-human Phase 1 clinical study. The agreement with DTRA is a strategic move to address the DoD’s objective of protecting U.S. Joint Forces from potential biological weapon threats. The DoD announced in December 2022 that it aims to move beyond the traditional ‘one bug, one drug’ approach and is seeking broad-spectrum drugs, as predicting which viruses or how many may be deployed in a biological threat scenario is challenging. Dr. Lederman emphasized that the collaboration with DTRA underscores Tonix Pharmaceuticals' commitment to advancing medical readiness and protection for military personnel. By developing a broad-spectrum antiviral agent, Tonix aims to provide a versatile and robust solution to potential viral threats, enhancing the preparedness and resilience of the U.S. military in diverse and unpredictable biological threat environments. The TNX-4200 program’s focus on creating an effective, orally available antiviral agent highlights Tonix’s innovative approach to addressing complex medical challenges. The successful development of this broad-spectrum antiviral could significantly impact the way viral infections are managed in military and potentially civilian populations, offering a proactive measure against a wide array of viral threats. Tonix Pharmaceuticals continues to be at the forefront of medical innovation, dedicated to developing cutting-edge solutions that meet the evolving needs of the healthcare and defense sectors. The support from the DoD through this substantial contract is a testament to the potential and importance of Tonix’s TNX-4200 program in safeguarding the health and readiness of military personnel against biological threats. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

July 19, 2024 12:48 PM Eastern Daylight Time

Video
Article thumbnail News Release

Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test

Mainz Biomed N.V.

Mainz BioMed CEO Guido Baechler joined Steve Darling from Proactive to announce the company has submitted an application to the U.S. Food and Drug Administration requesting Breakthrough Device Designation for its innovative non-invasive Next Generation colorectal cancer screening product. This product incorporates a novel portfolio of mRNA biomarkers. Achieving this designation could potentially expedite the approval process, significantly benefiting early cancer detection efforts. Baechler emphasized that the regulatory submission is backed by consistently strong results from the company's clinical studies, ColoFuture and eAArly Detect, as well as data from a comprehensive pooled study encompassing both the European and U.S. cohorts, which were presented at ASCO 2024. These studies have culminated in the final configuration of the Next Generation Test. This test integrates the Fecal Immunochemical Test with proprietary mRNA biomarkers and is enhanced by an advanced AI and machine learning algorithm. This integrated approach is set to be employed in the FDA premarket approval study. The Next Generation Test configuration was rigorously evaluated in a clinical setting involving 295 subjects from 21 specialized gastroenterology centers across the United States. The results underscored the exceptional efficacy of Mainz Biomed’s multimodal screening test, which allows for precise differentiation among colorectal cancer, advanced adenomas, non-advanced adenomas, and samples with no pathological findings. The FDA’s Breakthrough Devices Designation program is designed to accelerate the development, assessment, and review of medical devices and combination products that provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions. This designation for Mainz BioMed's colorectal cancer test could pave the way for quicker market access and wider availability of this critical diagnostic tool. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

July 19, 2024 12:38 PM Eastern Daylight Time

Video
Article thumbnail News Release

Immersive Engagement Is The Future – CEO Speaks About Company's Innovations That Keep Pushing What's Possible

Benzinga

By Johnny Rice, Benzinga Ann Hand, CEO of Super League Enterprise Inc (NASDAQ: SLE), was recently interviewed by Benzinga. Super League helps brands reach Gen Z and Gen Alpha in the 3D environments that they frequent. Platforms like Roblox (NYSE: RBLX), Fortnight and others represent significant opportunities to marketers as they allow for very interactive and immersive experiences. Ms. Hand spoke about the exciting developments her company has been making, such as SOUNDZ, its latest tool for driving real engagement and commerce. Learn more here: Featured photo by Vinicius "amnx" Amano on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

July 19, 2024 09:00 AM Eastern Daylight Time

Video Image
Article thumbnail News Release

Old Slip Capital Announces New Miami Office, Issues Advisory for ERISA by James Lukezic, Managing Director

Rev Up Marketers

Old Slip Capital has announced the opening of its new office in Miami, FL. The company has also issued an important advisory to plan sponsors, pointing to the advantages of trusting ERISA Fiduciary Advisors. Old Slip Capital's new office in Miami will further add a growth potential to its prospects. It has also shared insights for Plan Sponsors to help them derive the best from ERISA. The advisory focuses on explaining the difference between an ERISA Fiduciary Advisor and a Standard Broker or Advisor, and helps in understanding that selecting a Standard Broker or Advisor is simply not good enough. According to James Lukezic, Managing Director at Old Slip Capital, there are some obvious dangers of not hiring an ERISA Fiduciary Advisor under section 3(38) or 3(21) or both: "Plan Sponsors think that simply having an Advisor at the table is enough until they (Plan Sponsor) realize that a Standard or Retail Advisor is giving them arm’s length advice and not truly taking on liability or responsibility for that advice. With a sanctioned ERISA Fiduciary Advisor, Plan Sponsors can shift that liability to the ERISA Advisor and his or her firm; that includes personal liability on the part of the investment committee members". The advisory goes on to point out that plaintiffs’ class action lawyers in fiduciary breach lawsuits, the Department of Labor in ERISA plan audits, courts, and insurers have focused increased attention on how well ERISA plan fiduciaries follow procedural due process. Actions (or inactions) of committees and individual investment committee fiduciaries are scrutinized and judged in increasing detail, causing fiduciaries to wonder if they are up to date on all of the best practices for plan governance. According to Old Slip Capital, understanding the roles of Fiduciaries and the types of Fiduciaries generally causes confusion. There are Trust Fiduciaries, Administrative Fiduciaries and ERISA Fiduciaries; the latter being the most important. The role of the ERISA Fiduciary is critical, as this advisor is the glue that holds the Retirement Plan together, his or her advice to the Investment Committee steers the success of the plan in a big way. The advisory further explains that competence to act as a fiduciary on the investment committee means more than just having subject matter expertise. It also means having the time needed to devote to the fiduciary role. Putting aside the potential conflicts of interest that a director would face in switching hats from corporate director to plan fiduciary, even a director with the requisite expertise to act as a fiduciary, typically lacks the time (and probably the inclination) to perform more than an oversight role. Furthermore, the Board of Directors should never be left in the position of acting as the Investment Committee. Unfortunately, this is precisely the form of fiduciary governance structure that is in place with the overwhelming majority of employer sponsored plans. Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements. Contact Details Old Slip Capital Partners James Lukezic james@oldslipcap.com Company Website https://www.oldslipcap.com/

July 19, 2024 08:41 AM Eastern Daylight Time

Image
Article thumbnail News Release

The Rising Importance Of Minor Cannabinoids In The Growing Edible Market

Benzinga

By Kyle Anthony, Benzinga With society’s growing acceptance of cannabis consumption, a segment that has risen in popularity is edibles, which are simply products containing cannabinoids that one can eat or drink. While edibles containing cannabinoid compounds, such as THC (tetrahydrocannabinol), which induces a euphoric feeling, or CBD (cannabidiol), which has therapeutic attributes, are familiar to many, edibles containing minor cannabinoids are gaining traction among consumers due to the compound’s unique properties and potential health benefits. As such, the minor cannabinoid-infused edibles market stands at the precipice of potentially remarkable growth, fueled by discernible shifts in consumer behavior. The 2023 Minor Cannabinoid Market Recently, BayMedica, a firm focused on producing and commercializing rare cannabinoids and a subsidiary of InMed Pharmaceuticals (NASDAQ: INM), released a report detailing the growth of the minor cannabinoid market in 2023. The report utilized data from Headset, the largest dataset in the cannabis industry. It focuses on the growth, competition and consumer habits associated with minor cannabinoid-infused edibles in ten regulated cannabis states, which represent 85 million of the 158 million people living in areas where recreational cannabis is legal. The edible market experienced a robust 5.4% revenue surge in 2023, totaling $2.097 billion for the year. This growth was driven partly by innovative developments with minor cannabinoids. Gummies, a subset of the edible product category, exhibited strong sales, while minor cannabinoid-infused edibles witnessed an impressive 47% year-over-year growth, with sales totaling $391 million for the year. While there was a slight decline (i.e., from $14.29 to $12.54) in the average edible item price, the increased demand by consumers, strong growth prospects of the category and reduced input production costs were factors that appealed to cannabinoid brands seeking to gain strategic positioning in the industry. Minor Cannabinoids Explained Minor cannabinoids are naturally occurring compounds found in cannabis plants, distinct from the more well-known cannabinoids like THC and CBD. While THC and CBD dominate in terms of quantity and research focus, minor cannabinoids are changing the cannabinoid landscape due to their holistic capabilities. Minor cannabinoids are found in much smaller quantities than their more abundant counterparts THC and CBD, and are relatively rare in the full spectrum of cannabinoids that are present in a fully mature cannabis plant. Some notable minor cannabinoids include: Cannabichromene (CBC): CBC is recognized as a "booster" for other cannabinoids and is known for its interaction with the body's natural endocannabinoid, anandamide (also known as the bliss molecule). CBC seems to prevent the reabsorption of anandamide, enabling this bliss molecule to remain in the bloodstream for a longer duration. Tetrahydrocannabivarin (THCV): THCV is non-psychoactive and has a chemical structure similar to THC but produces different effects. It may act as an appetite suppressant, making it of interest for weight loss and for reducing unwanted food cravings that are typical with adult-use cannabis products. Additionally, As a CB1 receptor neutral antagonist, it can stimulate focus and energy, opening it up to a wide range of potential applications as an ingredient in both topical and ingestible products. Cannabidivarin (CBDV): CBDV is similar to CBD in its lack of psychoactive effects. Possible use cases for this minor cannabinoid span from the promotion of brain health and immune health to gut health. Cannabinol (CBN): CBN is formed as THC degrades and is mildly psychoactive. It is known for its potential sedative effects, which could be useful for treating insomnia. Additionally, CBN may have antibacterial properties and could aid in pain relief​. All cannabinoids work with the endocannabinoid system (ECS), which was only discovered in the late 1980’s. Every human being has an endocannabinoid system, and every cell type in the body has cannabinoid receptors that work as lock and key, with the over 140 cannabinoids that are known to exist. The ECS regulates and controls many of the body’s most critical functions, and it has been hypothesized that ECS activity may have therapeutic potential in almost all diseases affecting humans. Some of the more powerful cannabinoids, sometimes known as minor or rare cannabinoids, are impractical to extract either because they are represented in such small quantities in the plant or because their separation from other cannabinoids is cost-prohibitive. However, advancements in biosynthesis and synthetic chemistry, such as those utilized by companies like BayMedica, LLC, enable the production of these cannabinoids at commercial scales, paving the way for new therapeutic applications​. Minor Cannabinoids Gaining Momentum In 2023, 24 of the top 50 selling edibles incorporated minor cannabinoids, reflecting a significant shift in market trends. The innovation underpinning this material adoption speaks to the commitment of leading edible brands that are identifying formulations that resonate with a growing and diverse consumer base. This strategic action helped brands counter price compression by establishing a premium price and propelled the growth of minor-infused edible revenue. As detailed in the report, brands incorporating minor cannabinoids in cannabis products strategically command a premium, boasting a 6.3% higher average item price than products with standard THC formulations. This pricing trend reflects market recognition and a willingness to pay more for products enriched with minor cannabinoids, providing an opportunity for differentiation in a crowded market. It also gives credence to the entourage effect, a theory that various cannabis compounds work together to create specific effects and benefits. Using this theory, combining minor cannabinoids with major cannabinoids like THC and CBD allows for more medicinal benefits upon consumption, like pain relief. Cannabis brands incorporating minor cannabinoids also enjoy a remarkable 73% higher average EQ (Equivalent) price compared to THC-only counterparts. The use of EQ pricing is essential for fair product comparison, considering factors like potency or weight and highlighting consumers' tangible willingness to pay more for the inclusion of minor cannabinoids. Finally, given the diverse nature of minor cannabinoids, the products have high customer value and appeal. Tapping into their therapeutic properties empowers consumers to experience various health and wellness benefits, fostering a healthier and more balanced lifestyle. Commercial Adoption Commercialization of minor cannabinoids via edibles has provided insight into which minors are resonating with consumers. As illustrated in the report, CBN has established and maintained sales leadership within the minor cannabinoid landscape. Given its potential sedative effects, it can be hypothesized that consumer demand is being driven by individuals using it as a sleep aid. While CBG continues to exhibit strong year-over-year sales, market analysts project a potential deceleration in the future. Projections suggest that CBG, once the minor cannabinoid leader, may make way for emerging cannabinoids to take the forefront. In contrast to prior years, both CBC and THCV exhibited strong sales in 2023. For CBC, as research on its potential benefits as a mood enhancer gains momentum, its popularity in consumer preferences is likely to fuel sustained growth in sales, positioning it as a key player in the evolving cannabis market. THCV witnessed a substantial 140% year-over-year growth. Its improved affordability due to production enhancement made by lead processors like BayMedica has made THCV more accessible in the edibles market. Furthermore, rising awareness of its physical energy and appetite-suppressing effects, especially when combined with THC variants, positions it as a key player in shaping the evolving landscape of cannabinoid-based products. The Path Forward The edibles market is witnessing a paradigm shift as consumers are redefining their priorities around cannabis consumption, moving away from smoking in favor of the targeted therapeutic effects and consistent experiences offered by edibles. This move means the cannabis product landscape will be transformed in the coming years; as such, edible brands will need to align with the evolving needs of consumers, steering the industry towards a future where minor cannabinoids in edibles take center stage in the pursuit of holistic well-being. As a stakeholder in this industry transformation, BayMedica continues to focus on scaling its operations and expanding its product offerings to meet the growing demand for high-quality cannabinoids in various applications that may be used by a growing customer base. Featured photo by Elsa Olofsson on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

July 19, 2024 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

Benchmark International Successfully Facilitated the Transaction Between Micro-Precision Technologies, Inc. and Great River Capital Partners

Benchmark International

Benchmark International has successfully facilitated the transaction between Salem, NH-based Micro-Precision Technologies, Inc. (“MPT”) and Boston, MA-based Great River Capital Partners (“Great River”). MPT designs and manufactures high-performance microelectronics for harsh environments and high-reliability applications. The company’s offerings primarily include thick-film ceramic substrates, hybrid micro-electronic manufacturing, and obsolete semiconductor manufacturing. “The Benchmark International team understood early that MPT is a highly differentiated asset, given its Defense Logistics Agency standards certification and highly valuable niche manufacturing capabilities,” commented Benchmark Senior Transaction Director William Sullivan. “This opportunity garnered immediate interest from very high-quality buyers, as we knew it would. Ultimately, Great River proved to be the perfect fit, with its narrow focus on mid-sized industrial technology companies, highly competent team, and HQ and management sitting close to MPT’s home base. To extend the metaphor, we think this will be a home run for both teams, and we were proud to be a part of it.” MPT serves the defense, industrial controls, commercial aviation, semiconductor capital equipment (semi-cap), communications equipment, and space & biological industries across the US and internationally. Founded in 2012 by Mr. Adrian Pyke, the company is one of only 30 worldwide certified by the Defense Logistics Agency (DLA) to the MIL-PRF-38534 quality standard. Great River Capital Partners is a private equity investment firm with a narrow focus on acquiring mid-sized industrial technology and services companies. Leveraging 30 years of collective investing experience, the firm partners with business owners to create long-term value through organic growth initiatives and strategic add-on acquisitions. Americas: Sam Smoot at +1 (813) 898 2350 / Smoot@BenchmarkIntl.com Europe: Michael Lawrie at +44 (0) 161 359 4400 / Lawrie@BenchmarkIntl.com Africa: Anthony McCardle at +27 21 300 2055 / McCardle@BenchmarkIntl.com ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 zoeller@benchmarkintl.com Company Website https://www.benchmarkintl.com/

July 19, 2024 06:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Basile International Legal Firm Sets New Standards in International Debt Collection

Rev Up Marketers

Basile International Legal Firm, a rising star in the legal industry, has gained substantial recognition for its groundbreaking approach to international debt collection. Founded by seasoned professionals from diverse legal backgrounds, the firm is bringing fresh and effective solutions to a complex industry. Top-Notch Expertise Basile International Legal Firm prides itself on its team of highly skilled attorneys, who specialize in business-to-business debt collection. With a deep understanding of international legislation, these legal experts are adept at enforcing foreign judgments and managing insolvency issues with precision. This extensive knowledge ensures the firm’s success in recovering debts across borders, providing clients with the confidence that their cases are in capable hands. Clear and Affordable One of the standout features of Basile International Legal Firm is its commitment to transparency in pricing. Clients are informed of the fees upfront, with no hidden charges. This clear, competitive pricing model makes debt recovery services accessible for small and medium-sized enterprises. Additionally, the firm’s innovative “WE WIN, NO FEE” policy ensures that clients only pay if the firm successfully recovers their debts. This approach not only minimizes financial risk for clients but also underscores the firm’s dedication to achieving results. Customized Solutions Basile International takes pride in offering personalized advice tailored to the unique circumstances of each debt collection case. The firm leaves no stone unturned, employing a mix of negotiation and legal action to settle outstanding debts. This customized approach is particularly effective in international debt collection, where the complexities of cross-border disputes require careful and strategic handling. Wide Reach With offices in both the Netherlands and Italy, Basile International Legal Firm operates extensively within the European Union and beyond. Their global network of associates enhances their ability to recover debts from defaulters who have relocated. While the firm always aims for amicable settlements, they are fully prepared to pursue litigation if necessary, ensuring a comprehensive range of international debt collection services. Comprehensive Services in International Debt Collection Basile International Legal Firm’s specialization in international debt collection offers a suite of services designed to meet the needs of businesses worldwide: International Debt Collection B2B: Assisting companies in recovering debts from international clients, including unpaid invoices and unfulfilled contracts. Extrajudicial Debt Recovery: Employing negotiation and mediation to resolve debts outside of court. Judicial Debt Recovery: Providing support during legal proceedings in the creditor's or debtor's country, based on applicable laws. Insolvency and Bankruptcy Procedures: Navigating the complexities of insolvency to recover debts even in cases of bankruptcy. International Trade Disputes: Resolving conflicts arising from international trade agreements. Drafting Terms and Conditions: Offering legal expertise in drafting comprehensive terms and conditions for businesses. About Basile International Legal Firm Basile International Legal Firm, with registered offices in the Netherlands and Italy, is a premier law firm specializing in international debt collection. A proud member of the Italian Chamber of Commerce for Holland, the firm is dedicated to helping companies recover their credits due from international customers. Whether through extrajudicial or judicial means, Basile International offers comprehensive support tailored to the needs of businesses facing cross-border debt challenges. Their commitment to transparency, affordability, and personalized service has set them apart in the industry. The firm’s innovative “WE WIN, NO FEE” policy further underscores their dedication to client success, minimizing costs and maximizing recovery. LinkedIn: https://www.linkedin.com/in/aleena-alii Contact Details Basile International Legal Firm Aleena Farid Public Relation and HR Manager +31 294 788 100 info@basileinternational.com Company Website http://www.basileinternationallegalfirm.com/

July 19, 2024 04:29 AM Eastern Daylight Time

Image
Article thumbnail News Release

Perú introdujo diez nuevas rutas para acceder al Santuario Histórico de Machupicchu

Promperu

Perú introdujo diez nuevas rutas para acceder al Santuario Histórico de Machupicchu durante la temporada alta, del 1 de junio al 15 de octubre de 2024 y del 30 al 31 de diciembre de 2024. Además, dentro de este periodo se superará la capacidad máxima de visitantes a esta maravilla del mundo. ampliado a 5600 por día. Las rutas se articulan y programan con aforos y turnos establecidos con el fin de preservar el patrimonio arqueológico y garantizar una experiencia óptima al visitante. Perú ha desarrollado iniciativas para asegurar la sostenibilidad a largo plazo de su sector turístico. El compromiso del país con prácticas turísticas sostenibles protege sus destinos emblemáticos. Por ejemplo, Machu Picchu es el primer destino turístico en lograr la certificación internacional de carbono neutral. PROMPERÚ pone a disposición el número de WhatsApp (+51 944-492-314) de IPERÚ, miembro de la Red de Protección al Turista, disponible las 24 horas del día de lunes a domingo. Los viajeros pueden comunicarse con este número para recibir información y asistencia. El servicio IPERÚ, prestado por el gobierno de forma gratuita, ofrece a los turistas información oficial y actualizada sobre el país. Una infografía detallada con los atractivos de Machupicchu que se incluyen en cada ruta se puede descargar aquí. Comisión de Promoción del Perú para las Exportaciones y el Turismo (PROMPERÚ). Somos la agencia gubernamental encargada del desarrollo e implementación de estrategias globales para posicionar al Perú a través de la promoción de su imagen, destinos turísticos, exportaciones de valor agregado e inversiones. Contact Details José Carlos Collazo jcollazos@promperu.gob.pe Company Website https://www.promperu.gob.pe

July 18, 2024 03:00 PM Eastern Daylight Time

Image
12345 ... 3599